Sartorius expands production of key components for cell and gene thera...

Göttingen, Germany | September 18, 2025

• New GMP facility for transfection reagents of French sub-group Sartorius Stedim Biotech in Illkirch
• Facility equipped to support next-generation technologies in cell and gene therapies

Aerial view of Sartorius Stedim Biotech's site expansion in Illkirch, France

The life science group Sartorius has expanded the site of its French sub-group Sartorius Stedim Biotech in Illkirch, near Strasbourg. The state-of-the-art facility adds pharmaceutical-grade (GMP) production of transfection reagents, which are critical components for viral vector manufacturing for novel therapies. The investment underscores Sartorius' dedication to supporting customers in developing and producing cell and gene therapies, a rapidly growing segment in biopharmaceuticals.

"The expanded Illkirch site is a key manufacturing hub in our global network and enables us to even better help customers deliver advanced therapies to patients faster and more efficiently," said René Fáber, Member of the Sartorius Executive Board and CEO of Sartorius Stedim Biotech.

In total, the site has more than doubled in size and now covers more than 8,000 square meters of production, lab, and office space. The fully digitalized plant is designed to operate under the EU guidelines for sterile drug manufacturing (GMP Annex 1 standard) and combines flexibility for future growth with high environmental standards.

The Illkirch site expansion follows the recent completion of a major capacity upgrade in Aubagne, France. Sartorius is investing strategically in the expansion of its global development and manufacturing network in order to prepare the company for further organic growth and to ensure high delivery reliability and consistent product quality across all regions.

For more details, read the complete media release of Sartorius Stedim Biotech.